Polygenic prediction of bipolar disorder in a Latin American sample

• Published in: American journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 192; no. 7-8; pp. 139 - 146
• Main Authors: Cuellar-Barboza, Alfredo B, Prieto, Miguel L, Coombes, Brandon J, Gardea-Resendez, Manuel, Núñez, Nicolás, Winham, Stacey J, Romo-Nava, Francisco, González, Sarai, McElroy, Susan L, Frye, Mark A, Biernacka, Joanna M
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2023
• Subjects: Bipolar disorder; Bipolar Disorder - genetics; Bipolar Disorder - psychology; Genetic Predisposition to Disease; Genetics; Genome-Wide Association Study; Humans; Latin America; Multifactorial Inheritance - genetics; Phenotypic variations; Risk Factors; Schizophrenia - genetics; Latin America; bipolar disorder; diversity; polygenic risk score; Latin American
• ISSN: 1552-4841; 1552-485X
• DOI: 10.1002/ajmg.b.32936

To date, bipolar disorder (BD) genetic studies and polygenic risk scores (PRSs) for BD are based primarily on populations of European descent (EUR) and lack representation from other ancestries including Latin American (LAT). Here, we describe a new LAT cohort from the Mayo Clinic Bipolar Biobank (MCBB), a multisite collaboration with recruitment sites in the United States (EUR; 1,443 cases and 777 controls) and Mexico and Chile (LAT; 211 cases and 161 controls) and use the sample to explore the performance of a BD-PRS in a LAT population. Using results from the largest genome-wide association study of BD in EUR individuals, PRSice2 and LDpred2 were used to compute BD-PRSs in the LAT and EUR samples from the MCBB. PRSs explained up to 1.4% (PRSice) and 4% (LDpred2) of the phenotypic variance on the liability scale in the LAT sample compared to 3.8% (PRSice2) and 3.4% (LDpred2) in the EUR samples. Future larger studies should further explore the differential performance of different PRS approaches across ancestries. International multisite studies, such as this one, have the potential to address diversity-related limitations of prior genomic studies and ultimately contribute to the reduction of health disparities.